350 related articles for article (PubMed ID: 25591003)
1. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
[TBL] [Abstract][Full Text] [Related]
2. Functional interplay between MDM2, p63/p73 and mutant p53.
Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
[TBL] [Abstract][Full Text] [Related]
3. Impact of the K24N mutation on the transactivation domain of p53 and its binding to murine double-minute clone 2.
Zhan YA; Wu H; Powell AT; Daughdrill GW; Ytreberg FM
Proteins; 2013 Oct; 81(10):1738-47. PubMed ID: 23609977
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the p53-MDM2 pathway.
Åberg E; Saccoccia F; Grabherr M; Ore WYJ; Jemth P; Hultqvist G
BMC Evol Biol; 2017 Aug; 17(1):177. PubMed ID: 28774266
[TBL] [Abstract][Full Text] [Related]
5. p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX.
Levy R; Gregory E; Borcherds W; Daughdrill G
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30832340
[TBL] [Abstract][Full Text] [Related]
6. The MDMX acidic domain competes with the p53 transactivation domain for MDM2 N-terminal domain binding.
Song Q; Liu XQ; Rainey JK
Biochim Biophys Acta Mol Cell Res; 2022 Oct; 1869(10):119319. PubMed ID: 35780910
[TBL] [Abstract][Full Text] [Related]
7. Binding Kinetics of the Intrinsically Disordered p53 Family Transactivation Domains and MDM2.
Åberg E; Karlsson OA; Andersson E; Jemth P
J Phys Chem B; 2018 Jul; 122(27):6899-6905. PubMed ID: 29878773
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
9. Differences in the transactivation domains of p53 family members: a computational study.
Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
BMC Genomics; 2010 Feb; 11 Suppl 1(Suppl 1):S5. PubMed ID: 20158876
[TBL] [Abstract][Full Text] [Related]
10. P53 family: at the crossroads in cancer therapy.
Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
[TBL] [Abstract][Full Text] [Related]
11. Evolution of affinity between p53 transactivation domain and MDM2 across the animal kingdom demonstrates high plasticity of motif-mediated interactions.
Mihalič F; Åberg E; Farkhondehkish P; Theys N; Andersson E; Jemth P
Protein Sci; 2023 Jul; 32(7):e4684. PubMed ID: 37211711
[TBL] [Abstract][Full Text] [Related]
12. Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways.
Ha JH; Shin JS; Yoon MK; Lee MS; He F; Bae KH; Yoon HS; Lee CK; Park SG; Muto Y; Chi SW
J Biol Chem; 2013 Mar; 288(10):7387-98. PubMed ID: 23316052
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies raised against Xenopus p53 interact with human p73.
Le Bras M; Delattre V; Bensaad K; Blandino G; Soussi T
Oncogene; 2002 Feb; 21(8):1304-8. PubMed ID: 11850851
[TBL] [Abstract][Full Text] [Related]
14. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
[TBL] [Abstract][Full Text] [Related]
15. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
[TBL] [Abstract][Full Text] [Related]
16. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.
Burge S; Teufel DP; Townsley FM; Freund SM; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3142-7. PubMed ID: 19218448
[TBL] [Abstract][Full Text] [Related]
18. Subcellular distribution of p53 and p73 are differentially regulated by MDM2.
Gu J; Nie L; Kawai H; Yuan ZM
Cancer Res; 2001 Sep; 61(18):6703-7. PubMed ID: 11559539
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the Activity in the p53 Family Depends on the Organization of the Transactivation Domain.
Krauskopf K; Gebel J; Kazemi S; Tuppi M; Löhr F; Schäfer B; Koch J; Güntert P; Dötsch V; Kehrloesser S
Structure; 2018 Aug; 26(8):1091-1100.e4. PubMed ID: 30099987
[TBL] [Abstract][Full Text] [Related]
20. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
